chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: U
Vaccine: COVID19-2
Symptoms: No adverse event, Off label use, Therapeutic response unexpected
Clinical narrative: No adverse event; Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms; Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms; This spontaneous case was reported by a physician and describes the occurrence of OFF LABEL USE (Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms), THERAPEUTIC RESPONSE UNEXPECTED (Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms) and NO ADVERSE EVENT (No adverse event) in a patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for Long COVID.     No Medical History information was reported.    In 2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. In 2023, the patient experienced OFF LABEL USE (Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms) and THERAPEUTIC RESPONSE UNEXPECTED (Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, OFF LABEL USE (Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms), THERAPEUTIC RESPONSE UNEXPECTED (Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for OFF LABEL USE (Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms) and THERAPEUTIC RESPONSE UNEXPECTED (Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms).    This case contains information for the 32nd of 42 patients described by the reporter.  No concomitant drug was reported.  Reporter called in to report success of non-indicated use of vaccine to treat long-haul COVID symptoms and asking to connect with research team. Reporter had been administering the 65 plus bivalent dose to her patients who have symptoms of "long-haul COVID" and had seen 88-90% success rate in resolving the symptoms of long-haul COVID.  Vaccine was given to the patients for long COVID between March 2023 and 01-Aug-2023. 42 patients received bivalent boosters with 38 having improvement of symptoms off 50% or more. Patients treated for skin lesions, brain related problem, systolic blood pressure was 220, tachycardia greater than 150, and body aches.  No adverse reactions occurred.  No treatment drug was reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-735199 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-735199:Master case
Age: 71.0
Sex: M
Vaccine: RSV
Symptoms: Cough, Pain
Clinical narrative: Bad cough, body aches,
Sex: U
Vaccine: COVID19-2
Symptoms: No adverse event, Off label use
Clinical narrative: No adverse event; Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms; This spontaneous case was reported by a physician and describes the occurrence of OFF LABEL USE (Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms) and NO ADVERSE EVENT (No adverse event) in a patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for Long COVID.     No Medical History information was reported.    In 2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. In 2023, the patient experienced OFF LABEL USE (Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, OFF LABEL USE (Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for OFF LABEL USE (Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms).    This case contains information about patient 41 out of 42 patients. No concomitant medication was provided by reporter. Reporter had been administering the 65 plus bivalent dose to patients who have symptoms of long-haul COVID and had seen 88-90% success rate which was resolved in the symptoms of long-haul COVID. It was reported that, vaccine was given to patients for long COVID between Mar-2023 and 01-Aug-2023. 42 Patients received bivalent booster with 38 having improvement of symptoms of 50 percent or more. Vaccine was given within current guidelines except seven were under 65. Patients were treated for skin lesions, brain related problem, systolic blood pressure was 220, Tachycardia greater than or equal to 150 and body aches. No adverse reactions occurred. Treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-735199 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-735199:Master case
Sex: U
Vaccine: COVID19-2
Symptoms: No adverse event, Off label use, Therapeutic response unexpected
Clinical narrative: No adverse event; Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms; 42 patients received Bivalent Boosters with 38 having improvement of symptoms of 50 percent or more; This spontaneous case was reported by a physician and describes the occurrence of OFF LABEL USE (Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms), THERAPEUTIC RESPONSE UNEXPECTED (42 patients received Bivalent Boosters with 38 having improvement of symptoms of 50 percent or more) and NO ADVERSE EVENT (No adverse event) in a patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for Long COVID.     No Medical History information was reported.    In 2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. In 2023, the patient experienced OFF LABEL USE (Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms) and THERAPEUTIC RESPONSE UNEXPECTED (42 patients received Bivalent Boosters with 38 having improvement of symptoms of 50 percent or more). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, OFF LABEL USE (Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms), THERAPEUTIC RESPONSE UNEXPECTED (42 patients received Bivalent Boosters with 38 having improvement of symptoms of 50 percent or more) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for OFF LABEL USE (Administered Moderna Covid-19 Bivalent doses to treat long-haul COVID symptoms) and THERAPEUTIC RESPONSE UNEXPECTED (42 patients received Bivalent Boosters with 38 having improvement of symptoms of 50 percent or more).    Concomitant medication was not reported.  Vaccine was given to patients for long COVID between Mar-2023 and 01-Aug-2023. 42 patients received Bivalent Boosters with 38 having improvement of symptoms of 50 percent or more. Vaccine was given within current guidelines except seven were under 65. Patients were treated with skin lesions, brain, SBP 220, Tachycardia greater than or equal to 150 and body aches. Treatment medication was not reported.  This case contains information of 5th patient out of 42 reported by reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-735199 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-735199:Master case
Sex: U
Vaccine: COVID19-2
Symptoms: Illness
Clinical narrative: Sickness; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (Sickness) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILLNESS (Sickness). At the time of the report, ILLNESS (Sickness) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   This case contains information about patient 03 out of 04 patients. No concomitant medication was provided by reporter. Four adult  patient was impact due to Moderna COVID-19 Vaccine for Illness. Reporter assumed patient  get sick because of the vaccine . Treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-737834 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-737834:Patinet 3
Sex: U
Vaccine: COVID19-2
Symptoms: Illness
Clinical narrative: Sickness; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (Sickness) in a patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILLNESS (Sickness). At the time of the report, ILLNESS (Sickness) outcome was unknown.        The action taken with mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown) was unknown.   For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   This case contains information about patient 04 out of 04 patients. No concomitant medication was provided by reporter. Four adult patient was impact due to Moderna COVID-19 Vaccine for Illness. Reporter assumed patient get sick because of the vaccine. Treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-737834 (Linked Report).   Reporter did not allow further contact; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-737834:Patient 1
Age: 6.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Vial was initially stored in refrigerator on 10-JUL-2023 and administered to patient on 11-AUG-2023; No adverse event; Dose were administered after 30-day Use By Date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose were administered after 30-day Use By Date), PRODUCT STORAGE ERROR (Vial was initially stored in refrigerator on 10-JUL-2023 and administered to patient on 11-AUG-2023) and NO ADVERSE EVENT (No adverse event) in a 6-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7644C) for COVID-19 prophylaxis.     No Medical History information was reported.    On 11-Aug-2023, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 11-Aug-2023, after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose were administered after 30-day Use By Date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vial was initially stored in refrigerator on 10-JUL-2023 and administered to patient on 11-AUG-2023) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose were administered after 30-day Use By Date), PRODUCT STORAGE ERROR (Vial was initially stored in refrigerator on 10-JUL-2023 and administered to patient on 11-AUG-2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Dose were administered after 30-day Use By Date) and PRODUCT STORAGE ERROR (Vial was initially stored in refrigerator on 10-JUL-2023 and administered to patient on 11-AUG-2023).    Concomitant medication details not reported by the reporter. Vial was initially stored in refrigerator on 10-JUL-2023. Vial did not undergo any temperature excursion. Vial size was reported as 2.5 milliliter. Treatment details was not reported by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-737984 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-737984:
Age: 5.0
Sex: M
Vaccine: COVID19-2
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse event; Patient received a .25ml dose from pink cap and not blue cap vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (Patient received a .25ml dose from pink cap and not blue cap vaccine) and NO ADVERSE EVENT (No adverse event) in a 5-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 214K22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 24-Aug-2023, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On 24-Aug-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced WRONG PRODUCT ADMINISTERED (Patient received a .25ml dose from pink cap and not blue cap vaccine). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Patient received a .25ml dose from pink cap and not blue cap vaccine) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Patient received a .25ml dose from pink cap and not blue cap vaccine).    Concomitant medication not reported.   It was unknown if the patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.  No other adverse reactions were reported.  Treatment medication not reported.
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, COVID-19, COVID-19 pneumonia, Confusional state, Hypoxia
Clinical narrative: Presented from nrsg. home for confusion and hypoxia, recent covid+ infection, progressively worsening in resp. status. Tx for acute respiratory failure with hypoxia secondary to acute pneumonia due to COVID-19 virus infection w/ O2, steroids
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Pneumonia, Respiratory distress, SARS-CoV-2 test positive
Clinical narrative: Presented from nrsg. home for confusion and hypoxia, recent covid+ infection, progressively worsening in resp. status. Tx for acute respiratory failure with hypoxia secondary to acute pneumonia due to COVID-19 virus infection w/ O2, steroids
Age: 18.0
Sex: F
Vaccine: MNQ, MNQ
Symptoms: Extra dose administered
Clinical narrative: I gave the pt 2 meningococcal vaccines at one time. I have not been able to reach either parent or patient at this time to see if said patient has had any adverse reactions
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Bradycardia, COVID-19 pneumonia, Confusional state, Dyspnoea, Fall
Clinical narrative: Arrived to ER c/o fall at home, confusion, SOB, hypoxia, bradycardia. COVID + dx w/ COVID pna dx ER. Received O2 by NC, steroids, remdesivir, IS. Improved, discharged home on RA.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoxia, SARS-CoV-2 test positive
Clinical narrative: Arrived to ER c/o fall at home, confusion, SOB, hypoxia, bradycardia. COVID + dx w/ COVID pna dx ER. Received O2 by NC, steroids, remdesivir, IS. Improved, discharged home on RA.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Death, Dyspnoea, Endotracheal intubation, Pneumonia aspiration
Clinical narrative: Arrived with SOB and possible aspiration of vomit. COVID + in ER and dx with aspiration pna and COVID-19. Critically ill on arrival to ER in septic shock; intubated and on multiple pressors. Expired approx. 10 hrs after arrival; no COVID specific treatment initiated.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive, Septic shock
Clinical narrative: Arrived with SOB and possible aspiration of vomit. COVID + in ER and dx with aspiration pna and COVID-19. Critically ill on arrival to ER in septic shock; intubated and on multiple pressors. Expired approx. 10 hrs after arrival; no COVID specific treatment initiated.
Age: 62.0
Sex: F
Vaccine: VARZOS
Symptoms: Crystal urine present, Gait disturbance, Gout
Clinical narrative: Gout in third toe pad from the right big toe. Uric acid crystals. Hard to walk but managing okay.
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, COVID-19, COVID-19 pneumonia, Death, Dyspnoea
Clinical narrative: Tested positive for COVID 3 days PTA; arrived with worsening SOB, O2 requirements; acute on chronic respiratory failure 2/2 COVID-19 pna. Given Toci, steroids, singulair, pepcid, zinc, remdesivir, lovenox, zithromax. Progressed from HFNC to vent. Expired in hospital.
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Mechanical ventilation, SARS-CoV-2 test positive
Clinical narrative: Tested positive for COVID 3 days PTA; arrived with worsening SOB, O2 requirements; acute on chronic respiratory failure 2/2 COVID-19 pna. Given Toci, steroids, singulair, pepcid, zinc, remdesivir, lovenox, zithromax. Progressed from HFNC to vent. Expired in hospital.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Blood test, Musculoskeletal stiffness, Rheumatoid arthritis
Clinical narrative: Joint pain, morning stiffness Rheumatoid arteritis
Age: 73.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory distress syndrome, COVID-19, COVID-19 pneumonia, Diarrhoea, Dyspnoea
Clinical narrative: Diagnosed with COVID days PTA; admitted with worsening SOB, N/V/D; dx with COVID pna. progressed to severe with ARDS. Treated with O2, steroids, abx, toci, pepcid, singulair, zinc, remdesivir, ovenox, velteri/sildenafil. Required mechanical vent. Transferred to a medical facility at request of family.
Age: 73.0
Sex: M
Vaccine: COVID19
Symptoms: Mechanical ventilation, Nausea, Vomiting
Clinical narrative: Diagnosed with COVID days PTA; admitted with worsening SOB, N/V/D; dx with COVID pna. progressed to severe with ARDS. Treated with O2, steroids, abx, toci, pepcid, singulair, zinc, remdesivir, ovenox, velteri/sildenafil. Required mechanical vent. Transferred to a medical facility at request of family.
Age: 82.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, COVID-19 pneumonia, Cough, Dyspnoea, SARS-CoV-2 test positive
Clinical narrative: Arrived with cough, SOB, increased O2 needs. + COVID at urgent care day prior. Dx with COVID pna in ER. Received O2, steroids, zinc, singulair, remdesivir x2 days. DC home on normal O2 requirements.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Fungaemia, SARS-CoV-2 test positive
Clinical narrative: Originally admitted from SNF for pyelo and fungemia. COVID + on 1/10 prior to SNF dc. Active infection that required O2, steroids, zinc, singulair and remdesivir. DC to SNF on O2.
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, COVID-19 pneumonia, Dyspnoea, SARS-CoV-2 test positive
Clinical narrative: COVID+ 8 days PTA, arrived with worsening SOB. Admit for COVID pna. Recieved O2, steroids, vit-c, vit-d, zinc, IV zithromax, Baricitinib. Progressed to Airvo. Outside of treatment window for remdesivir. DC home on RA.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Acute kidney injury, Anticoagulant therapy, Atrial fibrillation, Bladder catheterisation, COVID-19
Clinical narrative: "REASON FOR ADMISSION Patient is a 82-year-old male with past medical history of BPH, hypertension, atrial fibrillation, possible dementia who is admitted here for petechiae due to obstructive uropathy/urinary retention, COVID asymptomatic. He has been medically stable for some days, AKI resolved, no hematuria. His foley will be removed at SNF on the morning of 8/29 prior to urology eval.   AKI due to obstructive uropathy/urinary retention, resolved Continue Foley.   Urology saw the patient, continue foley until follow-up with Urology outpatient for cystoscopy and voiding trial. His foley can be removed on 8/29 morning at SNF.  Patient is also on keflex, per prior chart review continue until follow up with urology.  Patient is stale for discharge today to SNF.   Hematuria, resolved Eliquis resumed   Hypokalemia Monitor and replace.   Hypophosphatemia Monitor and replace   A Fib/A Flutter with RVR, resolved Continue eliquis Continie BB, added cardizem on cardio recs.   Non sustained V tach overnight 16 run Asymptomatic. KCL replaced overnight, check Mag this am.   BPH Proscar and flomax"
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Haematuria, Hypokalaemia, Hypophosphataemia, Petechiae, SARS-CoV-2 test positive
Clinical narrative: "REASON FOR ADMISSION Patient is a 82-year-old male with past medical history of BPH, hypertension, atrial fibrillation, possible dementia who is admitted here for petechiae due to obstructive uropathy/urinary retention, COVID asymptomatic. He has been medically stable for some days, AKI resolved, no hematuria. His foley will be removed at SNF on the morning of 8/29 prior to urology eval.   AKI due to obstructive uropathy/urinary retention, resolved Continue Foley.   Urology saw the patient, continue foley until follow-up with Urology outpatient for cystoscopy and voiding trial. His foley can be removed on 8/29 morning at SNF.  Patient is also on keflex, per prior chart review continue until follow up with urology.  Patient is stale for discharge today to SNF.   Hematuria, resolved Eliquis resumed   Hypokalemia Monitor and replace.   Hypophosphatemia Monitor and replace   A Fib/A Flutter with RVR, resolved Continue eliquis Continie BB, added cardizem on cardio recs.   Non sustained V tach overnight 16 run Asymptomatic. KCL replaced overnight, check Mag this am.   BPH Proscar and flomax"
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Urinary retention, Urinary tract obstruction, Ventricular tachycardia
Clinical narrative: "REASON FOR ADMISSION Patient is a 82-year-old male with past medical history of BPH, hypertension, atrial fibrillation, possible dementia who is admitted here for petechiae due to obstructive uropathy/urinary retention, COVID asymptomatic. He has been medically stable for some days, AKI resolved, no hematuria. His foley will be removed at SNF on the morning of 8/29 prior to urology eval.   AKI due to obstructive uropathy/urinary retention, resolved Continue Foley.   Urology saw the patient, continue foley until follow-up with Urology outpatient for cystoscopy and voiding trial. His foley can be removed on 8/29 morning at SNF.  Patient is also on keflex, per prior chart review continue until follow up with urology.  Patient is stale for discharge today to SNF.   Hematuria, resolved Eliquis resumed   Hypokalemia Monitor and replace.   Hypophosphatemia Monitor and replace   A Fib/A Flutter with RVR, resolved Continue eliquis Continie BB, added cardizem on cardio recs.   Non sustained V tach overnight 16 run Asymptomatic. KCL replaced overnight, check Mag this am.   BPH Proscar and flomax"
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19 pneumonia, Cough, Dyspnoea, Exposure to SARS-CoV-2, Pyrexia
Clinical narrative: Arrived with cough, SOB, fevers x3 days after COVID exposure. Positive in ER, COVID pna w/ respiratory failure. Received O2, steroids, IV zithromax ans rocephin, vit-c, zinc, remdesivir. Improved and DC home with O2.
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Respiratory failure, SARS-CoV-2 test positive
Clinical narrative: Arrived with cough, SOB, fevers x3 days after COVID exposure. Positive in ER, COVID pna w/ respiratory failure. Received O2, steroids, IV zithromax ans rocephin, vit-c, zinc, remdesivir. Improved and DC home with O2.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Chills, Condition aggravated, Cough, Diarrhoea
Clinical narrative: Arrived w/ c/o N,V,D, fever, chills, aches. + COVID, gastroperesis flare 2/2 COVID infection. Received vit-c, singulair. Did not require O2. DC home.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Impaired gastric emptying, Nausea, Pain, Pyrexia, SARS-CoV-2 test positive
Clinical narrative: Arrived w/ c/o N,V,D, fever, chills, aches. + COVID, gastroperesis flare 2/2 COVID infection. Received vit-c, singulair. Did not require O2. DC home.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Arrived w/ c/o N,V,D, fever, chills, aches. + COVID, gastroperesis flare 2/2 COVID infection. Received vit-c, singulair. Did not require O2. DC home.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Chronic obstructive pulmonary disease, Condition aggravated, SARS-CoV-2 test positive
Clinical narrative: "  Patient is a 73 YO female with h/o COPD, lung cancer s/p treatment, DM2, CKD3, HTN, HLD, admitted with acute COPD exacerbation due to COVID. She was treated with usual care including prednisone, duonebs and pulmonary hygiene. Was give remdesivir as well for COVID-19 infection. Symptoms improved slowly over the course of several days. She was weaned off oxygen and returned to near baseline. Discharged home in good condition."
Age: 93.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19 pneumonia, Chronic kidney disease
Clinical narrative: Admit for COVID pna dx same day in clinic. Received O2, steroids, vit-c, zinc. No remdesivir due to CKD. Recovered and DC home on RA.
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Anticoagulant therapy, COVID-19, COVID-19 pneumonia, Chemotherapy, Dyspnoea
Clinical narrative: Arrived with SOB x2 days. COVID+ 1/18. Undergoing chemo for leukemia. Admit with COVID pna. Received O2, zinc, singulair, lovenox, steroids, cefepime, zithromax, vanc. DC home on RA.
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Leukaemia, SARS-CoV-2 test positive
Clinical narrative: Arrived with SOB x2 days. COVID+ 1/18. Undergoing chemo for leukemia. Admit with COVID pna. Received O2, zinc, singulair, lovenox, steroids, cefepime, zithromax, vanc. DC home on RA.
Age: 4.0
Sex: M
Vaccine: DTAP
Symptoms: Injection site erythema, Injection site swelling, Injection site warmth
Clinical narrative: Mom states Friday night after vaccine there was some puffiness at the site. Sunday it was red and hot at the site. this morning the redness has spread down his arm. Mom tried some Tylenol yesterday with no effect. Walk in treatment advised
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Decubitus ulcer, Infected skin ulcer, SARS-CoV-2 test positive, Urinary tract infection
Clinical narrative: Admitted for UTI and infected decub, found to be COVID+. Received vit-c and zinc. Did not require O2 or other targeted therapies. DC to LTAC for wound care needs on RA.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, COVID-19 pneumonia, Cough, Dyspnoea, SARS-CoV-2 test positive
Clinical narrative: Arrived with SOB and cough, positive outside COVID test 2 days PTA (though tested negative in hospital). Admit for COVID pna and bilat PEs. Given O2, steroids, molnupiravir. Improved rapidly and DC home.
Age: 28.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Blood test, Dizziness, Headache, Magnetic resonance imaging, Neck pain
Clinical narrative: Starting with headaches and lightheaded ness and neck pain that progressively has gotten worse over time and has turned into chronic pain. I have seen numerous doctors over time and have not gotten a real diagnosis. Several medications have done nothing from muscle relaxers, nsaids, anti depressants, anti inflammatorys.
Age: 28.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pain, X-ray
Clinical narrative: Starting with headaches and lightheaded ness and neck pain that progressively has gotten worse over time and has turned into chronic pain. I have seen numerous doctors over time and have not gotten a real diagnosis. Several medications have done nothing from muscle relaxers, nsaids, anti depressants, anti inflammatorys.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19 pneumonia
Clinical narrative: Admit for COVID pna. Given O2, steroids, remdesivir. Pt left AMA same day.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19 pneumonia
Clinical narrative: Admit for COVID pna. Received O2, steroids, rocephin, vit-c, zithromax, cefepime, vit-d, zinc. Improved to baseline home O2 and DC home with HHC.
Age: 87.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, COVID-19 pneumonia, Respiratory failure, SARS-CoV-2 test positive, Vascular operation
Clinical narrative: Original admit for vascular sugery of LLE. Developed resp failure and tested positive for COVID 12/29/21; dx w/ COVID pna. Received HFO2, remdesevir, steroids, IV abx. Improved and DC to SNF.
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory distress syndrome, Asthenia, COVID-19 pneumonia, Cough, Death
Clinical narrative: Arrived w/ weakness and cough x1 month. Admit for COVID pna dx in ER. Out of window for monoclonal or remdesivir. Received  steroids, toci, rocephin and zithromax, singulair, zinc, pepcid, emergent dialysis. Developed ARDS. O2 needs progressed to 100% Bipap. Deteroirated and placed on comfort care. Expired in hospital.
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Dialysis, General physical health deterioration, Positive airway pressure therapy
Clinical narrative: Arrived w/ weakness and cough x1 month. Admit for COVID pna dx in ER. Out of window for monoclonal or remdesivir. Received  steroids, toci, rocephin and zithromax, singulair, zinc, pepcid, emergent dialysis. Developed ARDS. O2 needs progressed to 100% Bipap. Deteroirated and placed on comfort care. Expired in hospital.
Age: 60.0
Sex: F
Vaccine: TD, VARZOS
Symptoms: Condition aggravated, Injection site erythema, Injection site pain, Injection site warmth, Pain
Clinical narrative: on 8/25/23 - pt called in with moderate pain. No OTC taken as pt did not want to mask reaction ssx.  on 8/28/23 - pt seen with L deltoid erythema- arm is warm to touch and very painful (fire sensation)  - Tylenol, Aleve, Ice does not improve. No ssx of infection and defer ABX - to continue Tylenol/NSAID, Ice, and Benadryl.
Age: 82.0
Sex: F
Vaccine: COVID19
Symptoms: Pneumonia, Sepsis, Urinary tract infection
Clinical narrative: Hospitalization for Sepsis from UTI and/or Pneumonia on dates 8/21/2023-8/24/2023. Treated with dexamethasone, Remdesivir, vitamin C 1,000 mg PO daily, vitamin D 25 mcg PO daily, zinc 50 mg PO daily.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19
Clinical narrative: Hospitalization for COVID-19 on dates 8/21/2023- 8/22/2023. Treated with no COVID-related medications.
Age: 73.0
Sex: F
Vaccine: VARZOS
Symptoms: Balance disorder, Dizziness, Dysentery, Poor quality sleep, Vertigo
Clinical narrative: Wenesday Night at 11"00 I got out of bed, to use the bathroom, then when I got back in bed, my head was a little dizzy, then it became worse as I lay there.  I got up and went to the living room and sat down on the end of the couch, and my head was just spinning. So I was sitting up straight, and I put my chin down toward my chest, and it slowed it down. I leaned back on the couch and I stayed there all night and I didnt sleep very well. When I awoke, I was still dizzy, I couldnt really get up, and when I could get up I had to hold on to things so I wouldnt fall. I had to lean against the wall and all. It was like that all thursday and all Friday. Friday night it felt like it was easing up. Saturday I was able to go outside. It just about ended yesterday, Sunday. Thursday and Friday I had dysentery.
Age: 1.0
Sex: F
Vaccine: VARCEL
Symptoms: Blister, Scab
Clinical narrative: Patient had blisters on medial side of thighs, about a month later after vaccine administration, which slowly crusted over and resolved spontaneously without any intervention.
Age: 30.0
Sex: M
Vaccine: TYP
Symptoms: Lethargy, Loss of personal independence in daily activities, Somnolence
Clinical narrative: Lethargy and drowsiness the week following the vaccination. Found it hard to complete tasks I could do the month before like running and lifting weights.
Age: 0.75
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: The patient was administered an expired dose of COVID-19 vaccine after the unfrozen date.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: The patient was administered an expired dose of COVID-19 vaccine after the unfrozen date.
Age: 9.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: The patient was administered an expired dose of COVID-19 vaccine after the unfrozen date.
Age: 82.0
Sex: F
Vaccine: VARZOS
Symptoms: Dizziness, Injection site erythema, Injection site pain, Injection site pruritus, Injection site swelling
Clinical narrative: Very Red Very Itchy Dark Red Burning Hurting Swollen from shot site almost to elbow 1 large blister approximately center of swollen area Light headed Nausea  Healed now but continues to itch sometimes
Age: 82.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site vesicles, Nausea
Clinical narrative: Very Red Very Itchy Dark Red Burning Hurting Swollen from shot site almost to elbow 1 large blister approximately center of swollen area Light headed Nausea  Healed now but continues to itch sometimes
Age: 39.0
Sex: M
Vaccine: TDAP
Symptoms: Flank pain, Injection site swelling, Lymphadenopathy, Pain
Clinical narrative: Injection site swollen, pain radiating down his R flank, swollen lymph notes under R arm
Age: 83.0
Sex: F
Vaccine: COVID19
Symptoms: Breakthrough COVID-19
Clinical narrative: Covid-19 Breakthrough Infection
Age: 16.0
Sex: M
Vaccine: MNQ
Symptoms: Rash, Scratch, Skin warm, Swelling
Clinical narrative: started as warm to touch then to swell on Saturday, then on Sunday bumps and scratches appeared and swelling became bigger
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Retinal white dots syndrome
Clinical narrative: Mewds eye aka white dot syndrome to right eye.
Age: 5.0
Sex: F
Vaccine: DTAPIPV, MMRV
Symptoms: Injection site erythema, Injection site induration, Injection site swelling, Injection site warmth
Clinical narrative: 08/23/2023 Mom stated that patients arm was red, warm, hard and swollen.  Approximately 3 inches by 3 inches. On 08/26/2023, the arm started looking better and on 08/27/2023 was basically back to normal.  Mom gave child ibuprofen and did ice packs to area, while the arm was so red and swollen.
Age: 1.0
Sex: M
Vaccine: HEPA, HIBV, PNC13
Symptoms: Allergy test positive, Erythema, Food allergy, Lip erythema, Lip swelling
Clinical narrative: Patient had been able to freely eat shrimp, crab, and peanut butter many many times prior to turning 1yr old. Two weeks after turning 1yr (on 2/15/2020) he exhibited severe reaction to peanut butter touching his lips (instant swelling of lips to 3x normal size and redness around his lips and neck). We administered Benedryl immediately and watched symptoms which eventually subsided. We initiated formal allergy testing on 6/15/2020 and it was determined he had a severe allergy to shellfish and all nuts. The only new thing that had been introduced to his body was the 1/15/2020 & 2/6/2020 vaccines which may or may not have been the cause of the new allergies.
Age: 0.5
Sex: M
Vaccine: DTPPVHBHPB, HEP, DTPPVHBHPB, HEPA
Symptoms: Incorrect dose administered
Clinical narrative: Provider inadvertently ordered an additional hepatitis B vaccine during the 6-month visit.  A combo vaccine was ordered containing hep b, however the smartset for 6 month visit still contained a checked box for hep b. Offering 2 orders of hep b for this visit.
Age: 0.5
Sex: M
Vaccine: DTPPVHBHPB, HEP, DTPPVHBHPB, HEPA
Symptoms: Extra dose administered
Clinical narrative: Provider inadvertently ordered an additional hepatitis B vaccine during the 6-month visit.  A combo vaccine was ordered containing hep b, however the smartset for 6 month visit still contained a checked box for hep b. Offering 2 orders of hep b for this visit.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Obstructive sleep apnoea syndrome, Renal mass
Clinical narrative: OBSTRUCTIVE SLEEP APNEA 3/17/2023 RENAL MASS
Age: 4.0
Sex: M
Vaccine: MMRV
Symptoms: Local reaction
Clinical narrative: Large local reaction. Treatment = symptomatic care with ibuprofen and cetirizine. Outcome yet to be determined.
Age: 79.0
Sex: F
Vaccine: VARZOS
Symptoms: Hypoaesthesia, Injection site bruising, Injection site pain, Pain in extremity, Paraesthesia
Clinical narrative: Patient reports arm pain following administration, reports worsening in pain over the first 48 hours including bruising, pain at injection site and tingling or numbness in her hand.   Patient called her primary care office, PCP recommended patient call 911.  Patient called 911 but ultimately did not go the emergency department.  PCP's office was notified 8/28/23 and will follow up with patient.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Blood loss anaemia, Deep vein thrombosis
Clinical narrative: I82.401 ACUTE DVT OF RIGHT LEG, UNSPECIFIED VEIN 5/3/2023 ANEMIA DUE TO BLOOD LOSS
Age: 1.5
Sex: M
Vaccine: HEPA, HEPA
Symptoms: Underdose
Clinical narrative: Child was not supported properly by parent and staff during the vaccination. Less than half of the vaccine spilled out after child moving.  NP ordered additional Hep A for administration.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Computerised tomogram, Dysstasia, Gait disturbance, Hypersomnia, Laboratory test
Clinical narrative: Patient slept a great deal following vaccine.  On early morning of 5/11/21 while attempting to stand, patient reported "my legs did no work right" and lowered himself to LR floor where he stayed for the night.  Could  not raise himself; never walked interdependently afterward.   Admitted to hospital 5/16/21.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Musculoskeletal disorder
Clinical narrative: Patient slept a great deal following vaccine.  On early morning of 5/11/21 while attempting to stand, patient reported "my legs did no work right" and lowered himself to LR floor where he stayed for the night.  Could  not raise himself; never walked interdependently afterward.   Admitted to hospital 5/16/21.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Intentional overdose, Intentional self-injury, Obstructive sleep apnoea syndrome
Clinical narrative: G47.33 OBSTRUCTIVE SLEEP APNEA 5/1/2023 NARCOTIC OVERDOSE, INTENTIONAL SELF HARM, INIT
Age: 0.17
Sex: F
Vaccine: DTAPHEPBIP, HIBV, PNC13
Symptoms: Immediate post-injection reaction, Vomiting
Clinical narrative: Vomiting  immediately with administration
Age: 56.0
Sex: M
Vaccine: TDAP
Symptoms: Ear pain, Muscle operation, Muscle rupture, Muscle twitching, Pain in extremity
Clinical narrative: *8/22/2023 Patient contacted this office and reported on 9/7/2022 after vaccine he experienced bilateral facial twitching near his eyes.  Reports this resolved within 48 hours.  He also reported after receiving vaccine he went to a drive thru for lunch and while eating had bilateral inner ear pain and jaw pain while eating. Reports this resolved after 72 hours. Patient did not contact this office regarding these symptoms until 8/22/2023. *Patient reports on 9/18/2023 he picked up a rock and had Left arm retinaculum pain and swelling. Reports this resolved after 1 week.  *10/20/2022 Patient reports he experienced spontaneous bi-cep detachment from radius of the Left arm which he had repaired 2/2023. States he had to delay surgery due to work responsibilities. He reports he had outpatient surgery at Surgery Center. Patient reports that he believes the above events could be a possible vaccine injury. Informed patient that this nurse would complete a report and suggested he do the same. Patient states he is familiar with reporting system.  Regarding question 20 and 21 below, completed the question regarding same day facial twitching and inner ear/ jaw pain. Since the vaccine was given on the Right arm on 9/7/2022, I did not know if the injuries he reported regarding the Left arm applied to the questions.
Age: 56.0
Sex: M
Vaccine: TDAP
Symptoms: Pain in jaw, Peripheral swelling
Clinical narrative: *8/22/2023 Patient contacted this office and reported on 9/7/2022 after vaccine he experienced bilateral facial twitching near his eyes.  Reports this resolved within 48 hours.  He also reported after receiving vaccine he went to a drive thru for lunch and while eating had bilateral inner ear pain and jaw pain while eating. Reports this resolved after 72 hours. Patient did not contact this office regarding these symptoms until 8/22/2023. *Patient reports on 9/18/2023 he picked up a rock and had Left arm retinaculum pain and swelling. Reports this resolved after 1 week.  *10/20/2022 Patient reports he experienced spontaneous bi-cep detachment from radius of the Left arm which he had repaired 2/2023. States he had to delay surgery due to work responsibilities. He reports he had outpatient surgery at Surgery Center. Patient reports that he believes the above events could be a possible vaccine injury. Informed patient that this nurse would complete a report and suggested he do the same. Patient states he is familiar with reporting system.  Regarding question 20 and 21 below, completed the question regarding same day facial twitching and inner ear/ jaw pain. Since the vaccine was given on the Right arm on 9/7/2022, I did not know if the injuries he reported regarding the Left arm applied to the questions.
Age: 64.0
Sex: F
Vaccine: RSV
Symptoms: Joint swelling, Peripheral swelling
Clinical narrative: Patient reported swollen left wrist and hand on 8/27/2023.
Age: 58.0
Sex: F
Vaccine: COVID19-2
Symptoms: Swelling of eyelid
Clinical narrative: Transient episode of bilateral eyelid swelling. Onset 24 hours after vaccine administration, resolved 24 hours after onset spontaneously. Patient currently doing well, did not seek care.
Age: 20.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: The patient was administered an expired dose of COVID-19 vaccine after the unfrozen date.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Chronic respiratory failure, Respiratory failure, Sepsis
Clinical narrative: J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 4/17/2023 SEPSIS UNSPECIFIED ORGANISM
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: The patient was administered an expired dose of COVID-19 vaccine after the unfrozen date.
Age: 76.0
Sex: F
Vaccine: VARZOS
Symptoms: Discomfort, Injection site erythema, Injection site pruritus, Injection site swelling
Clinical narrative: Patient reports starting 8/26/23 that arm  was swollen in a contained area around injection site exhibiting redness and itching. Patient reports using hydrocortisone to reduce itching and was advised to take benadryl and use ice pack along with OTC tylenol or ibuprofen for discomfort.
Age: 72.0
Sex: M
Vaccine: HEPAB
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Patient received 3rd dose of twinrix on 08/26/2023 after receiving their 2nd dose on 08/16/2023. Patient has not reported any adverse events at the time of submitting this form.
Age: 17.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: Vaccine administered after the BUD. Parent has not reported an adverse reaction.
Age: 52.0
Sex: M
Vaccine: COVID19-2
Symptoms: Chills, Hyperhidrosis, Initial insomnia, Nausea, Pain
Clinical narrative: Chills, sweats, fever, headache, body aches, nausea but didn?t throw up, hard to fall asleep-only 1 hr sleep first night.
Age: 52.0
Sex: M
Vaccine: COVID19-2
Symptoms: Pyrexia
Clinical narrative: Chills, sweats, fever, headache, body aches, nausea but didn?t throw up, hard to fall asleep-only 1 hr sleep first night.
Age: 1.0
Sex: F
Vaccine: MMR, PNC15
Symptoms: Erythema, Pallor, Pruritus, Skin lesion, Skin warm
Clinical narrative: Hives ( large red macular lesions, blanches with pressure, warm to touch, itchy ) Treated with Benadryl
Age: 1.0
Sex: F
Vaccine: MMR, PNC15
Symptoms: Urticaria
Clinical narrative: Hives ( large red macular lesions, blanches with pressure, warm to touch, itchy ) Treated with Benadryl
Age: 80.0
Sex: F
Vaccine: RSV
Symptoms: No adverse event, Single component of a two-component product administered
Clinical narrative: patient received liquid component of vaccine in left arm on 8/23/23. it was discovered on 8/28/23 that patient did not receive powder. after contacting CDC advised to given patient another vaccine with both liquid and powder vials.  will follow up with patient in a couple days to see if any adverse events. patient does not currently report any side effects from liquid only injection.
Age: 50.0
Sex: F
Vaccine: VARZOS
Symptoms: Mobility decreased, Pain, Pain in extremity
Clinical narrative: Patient has pain on her right arm . Based on history it shows vaccine was left arm. She has complain of having soreness /pain. She states she cannot move her arm seen her pcp, her doctor things might be given on her wrong spot. Patient is seeing her orthopedic   on 08/29/2023
Age: 12.0
Sex: U
Vaccine: COVID19-2
Symptoms: No adverse event, Product storage error
Clinical narrative: Vaccine administered after the BUD. Parent has not reported an adverse reaction.
Age: 20.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: Vaccine administered after the BUD. Parent has not reported an adverse reaction.
Age: 14.0
Sex: M
Vaccine: TD
Symptoms: Wrong product administered
Clinical narrative: Td GIVEN INSTEAD OF Tdap
Age: 40.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: Patient had a visit on 7/14/2023 at 0930 .  Nurse remembers opening a new vial on this day.  Patient aslo got a monkeypox vaccine during this visit. on 7/14/2023, there were 2 doses extra left over in the same lot number, when there should have been 0 per internal inventory, Since it is not possible to pinpoint which doses caused the overage, it appears 1 or more doses given between 6/9/2023 and 7/7/2023 may have been expired- 12 hours after opening and reused, therefore all doses given during that period are considered to potentially be expired.
Age: 3.0
Sex: M
Vaccine: COVID19-2
Symptoms: Wrong product administered
Clinical narrative: Bivalent 5 years-11 years was given
Age: 11.0
Sex: F
Vaccine: TD
Symptoms: Wrong product administered
Clinical narrative: Td GIVVEN INSTEAD OF Tdap
Age: 0.75
Sex: M
Vaccine: COVID19
Symptoms: Incorrect product formulation administered
Clinical narrative: Patient received the pink cap vaccine instead of the blue cap vaccine.
Age: 17.0
Sex: M
Vaccine: COVID19-2
Symptoms: No adverse event, Product storage error
Clinical narrative: Vaccine administered after the BUD. Parent has not reported an adverse reaction.